PIK3CA and ovarian carcinoma: Our study demonstrated DHTS as a novel therapeutic agent of ovarian cancer, which disrupts PI3K pathway, and sensitizes cancer cells to platinum by inducing more DNA double‐strand breaks (DSBs).